Can a patient with multiple myeloma safely take Leqvio (inclisiran) for LDL‑cholesterol lowering?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can a Patient with Multiple Myeloma Take Leqvio?

Yes, a patient with multiple myeloma can safely take Leqvio (inclisiran) for LDL-cholesterol lowering, as there are no contraindications or drug interactions between inclisiran and multiple myeloma therapies.

Key Clinical Reasoning

The available evidence shows no overlap between inclisiran's mechanism of action and multiple myeloma treatment pathways:

  • Inclisiran's mechanism: A small interfering RNA (siRNA) that targets hepatic PCSK9 mRNA production, administered subcutaneously every 6 months after initial loading doses 1, 2

  • Multiple myeloma therapies: Include proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, elotuzumab), and corticosteroids 3, 4, 5

  • No documented interactions: None of the NCCN guidelines for multiple myeloma 3, 4, 5 or the Mayo Clinic recommendations 6 mention any contraindications or precautions regarding lipid-lowering therapies including PCSK9 inhibitors

Important Clinical Considerations

Cardiovascular Risk in Multiple Myeloma Patients

Multiple myeloma patients often have elevated cardiovascular risk due to:

  • Disease-related factors (hyperviscosity, amyloidosis)
  • Treatment-related cardiotoxicity, particularly with carfilzomib (hypertension in 12.2%, heart failure in 4.1%, ischemic heart disease in 1.8%) 7
  • Thrombotic risk from immunomodulatory drugs requiring anticoagulation 3, 4, 8

This makes aggressive LDL-C lowering particularly important in this population.

Practical Management Algorithm

  1. Assess baseline cardiovascular status before starting myeloma therapy, especially if carfilzomib is planned 7

  2. Initiate or optimize statin therapy as first-line lipid management

  3. Add inclisiran if:

    • LDL-C remains >70 mg/dL (1.8 mmol/L) on maximally tolerated statin 9, 10
    • Patient has established ASCVD or ASCVD risk equivalents
    • Medication adherence is a concern (twice-yearly dosing advantage) 11, 12
  4. Dosing: 284 mg subcutaneously at Day 1, Day 90, then every 6 months 1, 2

  5. Monitor: LDL-C reduction of 44-50% expected by Day 150-210, sustained through 4+ years 11, 12

Safety Profile

Inclisiran demonstrates excellent safety across diverse populations 11, 13, 14, 12:

  • Main adverse effect: injection site reactions (5.9-14%)
  • No hepatic, renal, or muscle toxicity signals
  • Anti-drug antibodies rare (4.6-5.5%) and clinically insignificant
  • No drug-drug interactions requiring dose adjustment

Specific Myeloma Treatment Considerations

No dose adjustments needed when combining inclisiran with:

  • Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
  • Immunomodulatory drugs (lenalidomide, pomalidomide, thalidomide)
  • Monoclonal antibodies (daratumumab, elotuzumab)
  • Corticosteroids (dexamethasone)

Continue standard myeloma supportive care:

  • Anticoagulation for immunomodulatory drugs (aspirin or therapeutic anticoagulation) 3, 4, 8
  • Herpes zoster prophylaxis for proteasome inhibitors 4
  • Bisphosphonates for bone disease 3

Clinical Pitfalls to Avoid

  • Don't delay lipid management: Cardiovascular disease is a significant cause of morbidity/mortality in myeloma patients, particularly those receiving cardiotoxic agents like carfilzomib 7

  • Don't assume statin intolerance: Inclisiran works effectively as monotherapy in statin-intolerant patients 14, but most myeloma patients can tolerate some statin therapy

  • Don't overlook renal function: While inclisiran has no renal dose adjustment requirements 1, many myeloma patients have renal insufficiency requiring careful monitoring of all medications

References

Guideline

multiple myeloma, version 3.2017, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Guideline

nccn guidelines insights: multiple myeloma, version 3.2018.

Journal of the National Comprehensive Cancer Network : JNCCN, 2018

Research

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2026

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Guideline

american association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Research

Efficacy and safety of inclisiran based on background lipid-lowering treatment.

European journal of preventive cardiology, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.